EP0497875B1
(de)
*
|
1989-10-24 |
2000-03-22 |
Isis Pharmaceuticals, Inc. |
2'-modifizierte nukleotide
|
US6395492B1
(en)
*
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6114513A
(en)
*
|
1990-01-11 |
2000-09-05 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized oligonucleotides
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5914396A
(en)
*
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US5852182A
(en)
*
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals Inc. |
Thiol-derivatized oligonucleosides
|
US5578718A
(en)
*
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
US5955589A
(en)
*
|
1991-12-24 |
1999-09-21 |
Isis Pharmaceuticals Inc. |
Gapped 2' modified oligonucleotides
|
US5623065A
(en)
*
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US6783931B1
(en)
|
1990-01-11 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6153737A
(en)
*
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5670633A
(en)
*
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US5646265A
(en)
*
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
US5677437A
(en)
*
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5386023A
(en)
*
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
US5792844A
(en)
*
|
1990-07-27 |
1998-08-11 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent nitrogen atoms
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US6262241B1
(en)
*
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
BR9106826A
(pt)
*
|
1990-08-13 |
1994-01-25 |
Isis Pharmaceuticals Inc |
Oligonucleotideo ou analogo de oligonucleotideo,processo para modular a producao de uma proteina por um organismo,para tratar um organismo e processos para sintetizar:9(2'-desoxi-2'-substituido-beta-d-ribofuranosil)-guanina e g('-desoxi-2'-fluor-beta-d-ribofuranosil)-guanina
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
DE59208572D1
(de)
*
|
1991-10-17 |
1997-07-10 |
Ciba Geigy Ag |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
US6335434B1
(en)
*
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US6831166B2
(en)
*
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US5332814A
(en)
*
|
1991-11-12 |
1994-07-26 |
Ciba-Geigy Corporation |
Process for the preparation of carbacyclic nucleosides, and intermediates
|
US5274157A
(en)
*
|
1991-11-12 |
1993-12-28 |
Ciba-Geigy Corporation |
Protected formylpentanediols, hydroxymethylpentanediols, process for their preparation and intermediates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
TW393513B
(en)
*
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
US6235887B1
(en)
*
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
US5700922A
(en)
*
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
DK0618925T4
(da)
|
1991-12-24 |
2012-07-09 |
Isis Pharmaceuticals Inc |
Antisense-oligonukleotider
|
US6277603B1
(en)
|
1991-12-24 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US20060270624A1
(en)
*
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5856455A
(en)
*
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
KR930016437A
(ko)
*
|
1992-01-22 |
1993-08-26 |
귀틀라인, 슈미트 |
올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
|
US5646261A
(en)
*
|
1992-01-22 |
1997-07-08 |
Hoechst Aktiengesellschaft |
3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
|
US6033909A
(en)
*
|
1992-01-22 |
2000-03-07 |
Hoechst Aktiengesellschaft |
Oligonucleotide analogs, their preparation and use
|
WO1993023570A1
(en)
*
|
1992-05-11 |
1993-11-25 |
Pharmagenics, Inc. |
Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
|
US20040127446A1
(en)
*
|
1992-05-14 |
2004-07-01 |
Lawrence Blatt |
Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
|
US5607691A
(en)
*
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
EP0577558A2
(de)
*
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
US6172208B1
(en)
|
1992-07-06 |
2001-01-09 |
Genzyme Corporation |
Oligonucleotides modified with conjugate groups
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US5652355A
(en)
*
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
US6087491A
(en)
*
|
1993-01-08 |
2000-07-11 |
Hybridon, Inc. |
Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
|
ATE150464T1
(de)
*
|
1993-01-08 |
1997-04-15 |
Hybridon Inc |
Synthese von dimer-blöcken und ihre verwendung bei der zusammensetzung von oligonukleotiden
|
DE69400208T2
(de)
*
|
1993-01-25 |
1996-11-28 |
Hybridon Inc |
Olionukleotidalkylphosphonate und -phosphonothioate
|
US6291438B1
(en)
|
1993-02-24 |
2001-09-18 |
Jui H. Wang |
Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
|
US5858988A
(en)
*
|
1993-02-24 |
1999-01-12 |
Wang; Jui H. |
Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
|
US5602118A
(en)
*
|
1993-03-16 |
1997-02-11 |
American Cyanamid Company |
2-thiosubstituted carbapenems
|
DE59407895D1
(de)
*
|
1993-05-12 |
1999-04-15 |
Novartis Ag |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
US5955591A
(en)
*
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
US5719273A
(en)
*
|
1993-06-14 |
1998-02-17 |
Nexstar Pharmaceuticals, Inc. |
Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
|
US5580972A
(en)
*
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
WO1995011910A1
(en)
*
|
1993-10-27 |
1995-05-04 |
Ribozyme Pharmaceuticals, Inc. |
2'-amido and 2'-peptido modified oligonucleotides
|
CA2180727A1
(en)
*
|
1994-01-26 |
1995-08-03 |
Alain De Mesmaeker |
Modified oligonucleotides
|
PT679657E
(pt)
*
|
1994-04-27 |
2003-11-28 |
Novartis Ag |
Nucleosidos e oligonucleotidos com grupos 2'-eter
|
US5646269A
(en)
*
|
1994-04-28 |
1997-07-08 |
Gilead Sciences, Inc. |
Method for oligonucleotide analog synthesis
|
DE4418691A1
(de)
*
|
1994-05-28 |
1996-02-22 |
Boehringer Mannheim Gmbh |
3'-(4'-) nicht-radioaktiv markierte Nukleoside und Nukleotide mit Aminocarbonsäure-, Peptid- oder Carbonsäure-Spacer
|
AU710074B2
(en)
*
|
1994-06-22 |
1999-09-16 |
Proligo Llc |
Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
|
US6232465B1
(en)
|
1994-09-02 |
2001-05-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US6166197A
(en)
*
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
US6222025B1
(en)
|
1995-03-06 |
2001-04-24 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
|
US5801155A
(en)
|
1995-04-03 |
1998-09-01 |
Epoch Pharmaceuticals, Inc. |
Covalently linked oligonucleotide minor grove binder conjugates
|
US6251939B1
(en)
|
1995-06-07 |
2001-06-26 |
Promega Biosciences, Inc. |
Carbamate-based cationic lipids
|
US20040220128A1
(en)
*
|
1995-10-26 |
2004-11-04 |
Sirna Therapeutics, Inc. |
Nucleic acid based modulation of female reproductive diseases and conditions
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
US5959100A
(en)
|
1996-03-27 |
1999-09-28 |
Nexstar Pharmaceuticals, Inc. |
Pyrimidine nucleosides as therapeutic and diagnostic agents
|
US5731181A
(en)
*
|
1996-06-17 |
1998-03-24 |
Thomas Jefferson University |
Chimeric mutational vectors having non-natural nucleotides
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US5945527A
(en)
*
|
1996-05-30 |
1999-08-31 |
Nexstar Pharmaceuticals, Inc. |
Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
|
US20050118605A9
(en)
*
|
1996-06-06 |
2005-06-02 |
Baker Brenda F. |
Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
|
JP2000512630A
(ja)
*
|
1996-06-06 |
2000-09-26 |
ノバルティス アクチエンゲゼルシャフト |
2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体
|
WO2005121371A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US5955590A
(en)
*
|
1996-07-15 |
1999-09-21 |
Worcester Foundation For Biomedical Research |
Conjugates of minor groove DNA binders with antisense oligonucleotides
|
US5902879A
(en)
*
|
1996-08-05 |
1999-05-11 |
Fidelity Systems, Inc. |
Methoxyoxalamido and succinimido precursors for nucleophilic addition to nucleosides, nucleotides and oligonucleotides
|
US6172217B1
(en)
|
1996-12-27 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Method of synthesizing phosphorothioate oligonucleotides
|
US6737236B1
(en)
|
1997-01-08 |
2004-05-18 |
Proligo, Llc |
Bioconjugation of macromolecules
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6127533A
(en)
*
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
AU731909B2
(en)
|
1997-07-01 |
2001-04-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US5985848A
(en)
*
|
1997-10-14 |
1999-11-16 |
Albert Einstein College Of Medicine Of Yeshiva University |
Inhibitors of nucleoside metabolism
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
US7427678B2
(en)
|
1998-01-08 |
2008-09-23 |
Sigma-Aldrich Co. |
Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
JP2002515514A
(ja)
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
AU745880B2
(en)
*
|
1998-05-21 |
2002-04-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6335439B1
(en)
|
1998-06-11 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Method of preparing phosphoramidites
|
US6124099A
(en)
*
|
1998-06-22 |
2000-09-26 |
The University Of Vermont And State Agricultural College |
Method for placing a photo-cross-linking agent at specific internal sites within the sequence of synthetic strands of ribonucleic acids
|
US6277967B1
(en)
*
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6226352B1
(en)
|
1998-09-08 |
2001-05-01 |
Veritas Pharmaceuticals, Inc. |
System and method for radiographic imaging of tissue
|
US6751290B2
(en)
|
1998-09-08 |
2004-06-15 |
Veritas Pharmaceuticals, Inc. |
Radiographic assessment of tissue after exposure to a compound
|
US6723746B2
(en)
|
1998-09-08 |
2004-04-20 |
Veritas Pharmaceuticals, Inc. |
Functional radiographic imaging methods and agents
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6277982B1
(en)
|
1999-08-20 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US7668658B2
(en)
|
1999-10-13 |
2010-02-23 |
Sequenom, Inc. |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
JP2003533971A
(ja)
*
|
1999-11-12 |
2003-11-18 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドを定量するための方法
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US20070026394A1
(en)
*
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
JP2003525037A
(ja)
*
|
2000-02-11 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Cd20およびnogo遺伝子発現の調節および診断のための方法および試薬
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
US7491805B2
(en)
*
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
DE60140658D1
(de)
|
2000-03-16 |
2010-01-14 |
Veritas Pharmaceuticals |
Radiographische bewertung von gewebereaktionen auf chemische verbindungen
|
NZ522045A
(en)
|
2000-03-30 |
2007-05-31 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
JP2003530841A
(ja)
*
|
2000-04-13 |
2003-10-21 |
トーマス エヌ. ワイト, |
治療的化合物および方法
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6958214B2
(en)
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US20060247194A1
(en)
*
|
2000-08-30 |
2006-11-02 |
Sirna Therapeutics , Inc. |
Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US6747142B1
(en)
|
2000-09-05 |
2004-06-08 |
Fidelity Systems, Inc. |
Multiple methoxyoxalamido and succinimido precursors for nucleophilic addition
|
US6548251B1
(en)
|
2000-09-05 |
2003-04-15 |
Fidelity Systems, Inc. |
Inhibition of molecular and biological processes using modified oligonucleotides
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
EP1873259B1
(de)
|
2000-12-01 |
2012-01-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Durch kleine 21nt- und 22nt-RNAs vermittelte RNA-Interferenz
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US6620586B2
(en)
*
|
2001-02-20 |
2003-09-16 |
Applied Gene Technologies, Inc. |
Methods and compositions for analyzing nucleic acids
|
ATE434936T1
(de)
|
2001-03-14 |
2009-07-15 |
Myriad Genetics Inc |
Tsg101-gag-wechselwirkung und ihre verwendung
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
EP1434778A4
(de)
|
2001-05-31 |
2005-07-13 |
Medarex Inc |
Cytotoxine und prodrugs, linker und stabilisatoren dafür
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CA2921821A1
(en)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
EP2174953A1
(de)
|
2001-09-18 |
2010-04-14 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003062452A2
(en)
|
2002-01-23 |
2003-07-31 |
Proligo, Llc |
Methods for the integrated synthesis and purification of oligonucleotides
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
EP1470148B1
(de)
|
2002-02-01 |
2012-07-18 |
Life Technologies Corporation |
Doppelsträngige oligonukleotide
|
US7553619B2
(en)
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
JP2005517450A
(ja)
*
|
2002-02-20 |
2005-06-16 |
サーナ・セラピューティクス・インコーポレイテッド |
短干渉核酸(siNA)を用いるRNA干渉媒介性標的発見および標的評価
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
US7582739B2
(en)
|
2002-03-11 |
2009-09-01 |
Epoch Biosciences, Inc. |
Negatively charged minor groove binders
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
AU2003228809A1
(en)
|
2002-05-03 |
2003-11-17 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
EP2116604A1
(de)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
|
EP2258847B2
(de)
|
2002-08-05 |
2020-07-01 |
Silence Therapeutics GmbH |
Weitere neue formen von interferierende rns moleküle
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
CN1694959B
(zh)
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
WO2004027030A2
(en)
*
|
2002-09-18 |
2004-04-01 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
|
EP2322535A3
(de)
|
2002-09-20 |
2011-09-28 |
Yale University |
Riboswitches, Verfahren für deren Anwendung, Zusammensetzungen damit
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
KR100481356B1
(ko)
*
|
2002-10-17 |
2005-04-07 |
이수화학 주식회사 |
2'-o-치환된 뉴클레오시드의 제조 방법
|
AU2003290598A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
AU2003295539A1
(en)
*
|
2002-11-15 |
2004-06-15 |
University Of Massachusetts |
Allele-targeted rna interference
|
CA2506127C
(en)
|
2002-11-15 |
2013-07-09 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
US8007804B2
(en)
|
2002-11-15 |
2011-08-30 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
EP2410332A1
(de)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Methode zur Identifizierung von purinergen Modulatoren des Geruchssystems
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20050037394A1
(en)
*
|
2002-12-03 |
2005-02-17 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
EP1570085A4
(de)
*
|
2002-12-03 |
2007-07-25 |
Archemix Corp |
Verfahren zur in-vitro-selektion 2'-substituierter nukleinsäuren
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
WO2004058987A2
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US20040231231A1
(en)
*
|
2002-12-20 |
2004-11-25 |
Cataldo Dominic A. |
Use of colloidal clays for sustained release of active ingredients
|
EP1585755B1
(de)
|
2002-12-31 |
2015-08-05 |
Sigma-Aldrich Co. LLC |
Verfahren und zusammenstellungen für die tandem-synthese von zwei oder mehr oligonukleotiden auf einen festen träger
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
US7468356B2
(en)
|
2003-02-11 |
2008-12-23 |
Antisense Therapeutics Ltd. |
Modulation of insulin like growth factor I receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040248841A1
(en)
*
|
2003-03-13 |
2004-12-09 |
Wang Jui H. |
Poly-DNP-siRNA
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US7276599B2
(en)
|
2003-06-02 |
2007-10-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
US7790691B2
(en)
*
|
2003-06-20 |
2010-09-07 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
|
US7947817B2
(en)
*
|
2003-06-30 |
2011-05-24 |
Roche Molecular Systems, Inc. |
Synthesis and compositions of 2'-terminator nucleotides
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
CA2536333C
(en)
*
|
2003-08-28 |
2013-01-08 |
Jan Weiler |
Interfering rna duplex having blunt-ends and 3'-modifications
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
AU2004274021B2
(en)
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ES2493016T3
(es)
|
2003-11-17 |
2014-09-11 |
Genentech, Inc. |
Composiciones que comprenden anticuerpos contra CD79b conjugados a un agente inhibidor del crecimiento o un agente citotóxico y procedimientos para el tratamiento de tumores de origen hematopoyético
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
EP2540734B1
(de)
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
EP1750776A2
(de)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonukleotide mit c5-modifiziertem pyrimidin
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP2290076B1
(de)
|
2004-05-28 |
2015-03-25 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit MicroRNA
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7745125B2
(en)
*
|
2004-06-28 |
2010-06-29 |
Roche Molecular Systems, Inc. |
2′-terminator related pyrophosphorolysis activated polymerization
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
CA2583375C
(en)
|
2004-09-02 |
2013-01-15 |
Yale University |
Regulation of oncogenes by micrornas
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006032144A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
|
NZ554277A
(en)
|
2004-10-20 |
2010-09-30 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin alpha 4 expression
|
WO2006137941A2
(en)
|
2004-11-12 |
2006-12-28 |
Ambion, Inc. |
Methods and compositions involving mirna and mirna inhibitor molecules
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
WO2006063031A2
(en)
|
2004-12-06 |
2006-06-15 |
Haplomics |
Allelic variants of human factor viii
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
WO2006110314A2
(en)
|
2005-03-25 |
2006-10-19 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
US7476733B2
(en)
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
EP1863908B1
(de)
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
US20090209621A1
(en)
|
2005-06-03 |
2009-08-20 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2007002528A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Yale University |
Anti-aging micrornas
|
EP1929012B1
(de)
|
2005-08-11 |
2010-10-06 |
Synthetic Genomics, Inc. |
Verfahren zur in vitro-rekombination
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
AU2006281569A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of CK19 expression
|
CA2619534A1
(en)
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating neurological disease
|
DK1931780T3
(en)
|
2005-08-29 |
2016-01-25 |
Regulus Therapeutics Inc |
Antisense-forbindelser med forøget anti-microrna-aktivitet
|
WO2007027775A2
(en)
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
CN101312748A
(zh)
|
2005-09-26 |
2008-11-26 |
梅达莱克斯公司 |
抗体-药物轭合物和使用方法
|
EP2189522A1
(de)
|
2005-10-14 |
2010-05-26 |
MUSC Foundation For Research Development |
PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP2325315B1
(de)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
EP1966377A2
(de)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-bp2-expression
|
JP2009524411A
(ja)
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
US7951934B2
(en)
|
2006-01-26 |
2011-05-31 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
6−修飾された二環式核酸類似体
|
JP5213723B2
(ja)
|
2006-01-27 |
2013-06-19 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
マイクロrnaの調節に使用するためのオリゴマー化合物及び組成物
|
EP2006293B1
(de)
*
|
2006-03-08 |
2016-08-24 |
Tokyo Institute Of Technology |
2'-hydroxylmodifiziertes ribonucleosidderivat
|
CA2873833A1
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2007125173A2
(en)
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
WO2007134014A2
(en)
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
EP2505649A1
(de)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation der Expression von GCGR
|
ES2389737T3
(es)
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
CN101479268B
(zh)
*
|
2006-06-27 |
2012-08-08 |
Cbt发展有限公司 |
2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用
|
RU2441875C2
(ru)
*
|
2006-06-27 |
2012-02-10 |
СиБиТи ДЕВЕЛОПМЕНТ ЛИМИТЕД |
Терапевтические соединения
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
US7640989B2
(en)
*
|
2006-08-31 |
2010-01-05 |
Halliburton Energy Services, Inc. |
Electrically operated well tools
|
AU2007299804A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
MiR-200 regulated genes and pathways as targets for therapeutic intervention
|
EP2145001A2
(de)
|
2006-09-19 |
2010-01-20 |
Asuragen, Inc. |
Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
|
EP2487240B1
(de)
|
2006-09-19 |
2016-11-16 |
Interpace Diagnostics, LLC |
Mikro-RNA, die differentiell in Pankreaserkrankungen exprimiert sind, und ihre Verwendung
|
WO2008036825A2
(en)
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
CA2665536C
(en)
|
2006-10-05 |
2016-02-16 |
Massachusetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
EP2104516B1
(de)
|
2006-11-01 |
2015-01-07 |
University of Rochester |
Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
JP2010510807A
(ja)
*
|
2006-11-27 |
2010-04-08 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
高コレステロール血症を治療するための方法
|
CA2672297A1
(en)
|
2006-12-11 |
2008-06-19 |
University Of Utah Research Foundation |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
EP2913341A1
(de)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
US7820810B2
(en)
*
|
2007-03-19 |
2010-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of 2′-O-substituted purine nulceosides
|
AU2008227458A1
(en)
|
2007-03-22 |
2008-09-25 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
AU2008251467B2
(en)
*
|
2007-05-11 |
2014-07-31 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
AU2008251381B2
(en)
|
2007-05-11 |
2014-10-30 |
The Johns Hopkins University |
Biomarkers for melanoma
|
KR101461659B1
(ko)
|
2007-05-11 |
2014-11-17 |
토마스 제퍼슨 유니버시티 |
신경변성 질환 및 장애의 치료 및 예방 방법
|
WO2008156987A2
(en)
|
2007-05-29 |
2008-12-24 |
Yale University |
Riboswitches and methods and compositions for use of and with riboswitches
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
EP2826863B1
(de)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nukleinsäurefunktionalisierte Nanopartikel für therapeutische Anwendungen
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US8278283B2
(en)
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009032693A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
CA2704737A1
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
JP5723154B2
(ja)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
RNAiにおけるオフターゲット表現型の影響を減少させるためのSiRNA配列非依存性修飾フォーマットおよびその安定化型
|
WO2009039442A1
(en)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
EP3100718B1
(de)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
JP5677703B2
(ja)
|
2008-01-10 |
2015-02-25 |
リサーチ ディベロップメント ファウンデーション |
Ehrlichiachaffeensisにのためのワクチンおよび診断
|
EP2265627A2
(de)
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009111375A2
(en)
*
|
2008-03-01 |
2009-09-11 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
|
CN102014932B
(zh)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
US20110105588A1
(en)
*
|
2008-03-12 |
2011-05-05 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
EP2285819B1
(de)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
MX2010011508A
(es)
|
2008-04-18 |
2011-05-03 |
Baxter Int |
Composicion basada en microesferas para prevenir y/o revertir la nueva presentacion de diabetes autoinmune.
|
EP2280995A2
(de)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Verfahren zur behandlung von entzündungen
|
CA2723716A1
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
EP2143726A1
(de)
|
2008-07-11 |
2010-01-13 |
Novosom AG |
Nukleinsäure, die zwitterionische Nukleotide enthält
|
WO2010006973A2
(en)
*
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of tgf-beta receptor genes
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US8901095B2
(en)
|
2008-07-29 |
2014-12-02 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
WO2010027832A1
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
EP2331690B1
(de)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
US8691971B2
(en)
|
2008-09-23 |
2014-04-08 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
|
US8501805B2
(en)
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
US8604192B2
(en)
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2334793B1
(de)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
|
ES2475065T3
(es)
|
2008-10-09 |
2014-07-10 |
Tekmira Pharmaceuticals Corporation |
Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
NZ592867A
(en)
|
2008-10-20 |
2013-05-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
PE20120115A1
(es)
*
|
2008-11-17 |
2012-02-20 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes del factor vii
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
CA2744207C
(en)
|
2008-11-24 |
2019-05-28 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
KR101749352B1
(ko)
|
2008-12-04 |
2017-06-20 |
큐알엔에이, 인크. |
Sirt1에 대한 천연 안티센스 전사체의 억제에 의해 sirt1 관련된 질환의 치료
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
EP3225281A1
(de)
|
2008-12-10 |
2017-10-04 |
Alnylam Pharmaceuticals, Inc. |
Gegen gnaq gerichtete dsrna-zusammensetzungen und verfahren zur expressionshemmung
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
AU2010211133A1
(en)
*
|
2009-02-03 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of PTP1B genes
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP3009150B1
(de)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
|
KR101805199B1
(ko)
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
신경교세포 유래된 신경영양성 인자 (gdnf)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (gdnf) 관련된 질환의 치료
|
EP2398815A4
(de)
*
|
2009-02-22 |
2013-10-16 |
Chemgenes Corp |
Synthese von ara-2'-o-methylnukleosiden, entsprechende phosphoramidite und oligonukleotide mit neuen modifikationen zur biologischen anwendung für therapeutika, diagnostika, g-tetraden-bildende oligonukleotide und apatamere
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
EP2408920B1
(de)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
KR20120022938A
(ko)
|
2009-04-15 |
2012-03-12 |
노오쓰웨스턴 유니버시티 |
올리고뉴클레오티드 관능화된 나노입자의 전달
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
EP2421972A2
(de)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
|
ES2661787T3
(es)
|
2009-05-01 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
|
NZ596186A
(en)
|
2009-05-05 |
2014-03-28 |
Alnylam Pharmaceuticals Inc |
Lipid compositions
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
KR20120069610A
(ko)
*
|
2009-05-15 |
2012-06-28 |
에프. 호프만-라 로슈 아게 |
글루코코르티코이드 수용체(gcr) 유전자의 발현을 억제하는 조성물 및 방법
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
EP2435571B1
(de)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
EP2443238B1
(de)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit paraoxonase 1 (pon1) mittels hemmung des natürlichen antisense-transkripts gegen pon 1
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
RU2566724C9
(ru)
|
2009-06-17 |
2019-03-12 |
Байоджен Ma Инк. |
Композиции и способы модуляции smn2 сплайсинга у субъекта
|
CN102597238B
(zh)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
|
WO2010151674A2
(en)
|
2009-06-26 |
2010-12-29 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
CA2779099C
(en)
|
2009-10-30 |
2021-08-10 |
Northwestern University |
Templated nanoconjugates
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
US20130084565A1
(en)
|
2009-11-03 |
2013-04-04 |
University Of Virginia Patent Foundation |
Versatile, visible method for detecting polymeric analytes
|
AR078921A1
(es)
|
2009-11-09 |
2011-12-14 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
|
AU2010321576A1
(en)
|
2009-11-23 |
2012-06-07 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011084455A2
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
KR101793753B1
(ko)
|
2009-12-23 |
2017-11-03 |
큐알엔에이, 인크. |
커플링방지 단백질 2(ucp2)에 대한 천연 안티센스 전사체의 저해에 의한 ucp2 관련 질환의 치료
|
EP2519633B1
(de)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
NO2521784T3
(de)
|
2010-01-04 |
2018-05-05 |
|
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
EP2524042A2
(de)
|
2010-01-12 |
2012-11-21 |
Yale University |
Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
|
BR112012017483A2
(pt)
*
|
2010-01-14 |
2019-09-24 |
Haplomics Inc |
previsão e redução de aloimunogenicidade de terapêuticos de proteína
|
WO2011091390A2
(en)
|
2010-01-25 |
2011-07-28 |
Opko Curna, Llc |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
US20110196016A1
(en)
*
|
2010-02-05 |
2011-08-11 |
Anke Geick |
Compositions and Methods for Inhibiting Expression of IKK2 Genes
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
EP2538981B1
(de)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
EP3214174B1
(de)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
JP6060071B2
(ja)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚および線維症適用におけるrna干渉
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
EP2625186B1
(de)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
EP2566966A4
(de)
|
2010-05-03 |
2013-12-11 |
Curna Inc |
Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt)
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
CA2799207C
(en)
|
2010-05-26 |
2019-03-26 |
Curna, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
CA2802049C
(en)
|
2010-06-07 |
2018-07-10 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
EP3369817A1
(de)
|
2010-07-06 |
2018-09-05 |
InteRNA Technologies B.V. |
Mirna und ihre diagnostischen und therapeutischen verwendungen bei erkrankungen und zuständen im zusammenhang mit melanomen oder bei erkrankungen und zuständen mit einem aktivierten braf-pfad
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
EP2851426B1
(de)
|
2010-10-18 |
2018-08-22 |
Arrowhead Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression von RRM2-Genen
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
EP2640853B1
(de)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation von alpha-synukleinexpression
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
EP2670404B1
(de)
|
2011-02-02 |
2018-08-29 |
The Trustees of Princeton University |
Sirtuin-modulatoren als modulatoren der virusproduktion
|
SI2670411T1
(sl)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
|
CA2825981A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
CA2826043A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
WO2012138453A1
(en)
|
2011-04-03 |
2012-10-11 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2012170945A2
(en)
|
2011-06-10 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
KR102395085B1
(ko)
|
2011-06-21 |
2022-05-09 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
|
CN112111492A
(zh)
|
2011-06-21 |
2020-12-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
AU2012275096B2
(en)
|
2011-06-29 |
2016-02-04 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
DK2726613T3
(en)
|
2011-06-30 |
2018-12-03 |
Arrowhead Pharmaceuticals Inc |
COMPOSITIONS AND PROCEDURES FOR INHIBITING GENEPRESSION OF HEPATITIS B VIRUS
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2739735A2
(de)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
EP2755692B1
(de)
|
2011-09-14 |
2020-11-25 |
Northwestern University |
Nanokonjugate zur durchquerung der blut-hirn-schranke
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
WO2013063519A1
(en)
|
2011-10-26 |
2013-05-02 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
EP2790736B1
(de)
|
2011-12-12 |
2018-01-31 |
Oncoimmunin, Inc. |
In-vivo-verabreichung von oligonucleotiden
|
EP4144378A1
(de)
|
2011-12-16 |
2023-03-08 |
ModernaTX, Inc. |
Modifizierte nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
DK2794627T3
(en)
|
2011-12-22 |
2019-01-14 |
Alios Biopharma Inc |
SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF
|
WO2013096837A1
(en)
|
2011-12-22 |
2013-06-27 |
Isis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
|
WO2013095132A1
(en)
|
2011-12-22 |
2013-06-27 |
Interna Technologies B.V. |
Mirna for treating head and neck cancer
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
SG11201405669XA
(en)
|
2012-03-13 |
2014-10-30 |
Swift Biosciences Inc |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
JP2015511494A
(ja)
|
2012-03-15 |
2015-04-20 |
キュアナ,インク. |
脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
JP2015513914A
(ja)
|
2012-04-02 |
2015-05-18 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
分泌タンパク質の産生のための修飾ポリヌクレオチド
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2852606B1
(de)
|
2012-05-22 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation der durch verstärker-rns vermittelten genexpression
|
WO2014004572A2
(en)
|
2012-06-25 |
2014-01-03 |
Isis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US20150297629A1
(en)
|
2012-07-27 |
2015-10-22 |
Isis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
CN104736551B
(zh)
|
2012-08-15 |
2017-07-28 |
Ionis制药公司 |
使用改进的封端方案制备寡聚化合物的方法
|
EP2897633B1
(de)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Behandlung von schmerzen durch hemmung von usp5-deubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
AR092982A1
(es)
|
2012-10-11 |
2015-05-13 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion de receptores androgenicos
|
WO2014059364A1
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
WO2014072357A1
(en)
|
2012-11-06 |
2014-05-15 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
SI2922554T1
(sl)
|
2012-11-26 |
2022-06-30 |
Modernatx, Inc. |
Terminalno modificirana RNA
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
EP3434774A1
(de)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
US9701708B2
(en)
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
WO2014127268A2
(en)
|
2013-02-14 |
2014-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014131892A1
(en)
|
2013-02-28 |
2014-09-04 |
Oligomer Sciences Ab |
Cell-penetrating oligonucleotides
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3404116B1
(de)
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
SG10201906382QA
(en)
|
2013-05-01 |
2019-08-27 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating hbv and ttr expression
|
RS57418B1
(sr)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 irnk sastavi i postupci njihove primene
|
TWI727917B
(zh)
|
2013-05-22 |
2021-05-21 |
美商阿尼拉製藥公司 |
TMPRSS6iRNA 組成物及其使用方法
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
AU2014280847B2
(en)
|
2013-06-13 |
2019-07-04 |
Antisense Therapeutics Ltd |
Combination therapy
|
EP3656386A1
(de)
|
2013-06-21 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
|
KR102236784B1
(ko)
|
2013-07-02 |
2021-04-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체의 조절인자
|
JP7019233B2
(ja)
|
2013-07-11 |
2022-02-15 |
モデルナティエックス インコーポレイテッド |
CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法
|
US10894963B2
(en)
|
2013-07-25 |
2021-01-19 |
Exicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
ES2773547T3
(es)
|
2013-08-08 |
2020-07-13 |
Scripps Research Inst |
Un procedimiento de marcaje enzimático específico de sitio de ácidos nucleicos in vitro mediante la incorporación de nucleótidos no naturales
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
KR102365486B1
(ko)
|
2013-08-28 |
2022-02-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
프리칼리크레인 (pkk) 발현의 조절
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
PE20190354A1
(es)
|
2013-09-13 |
2019-03-07 |
Ionis Pharmaceuticals Inc |
Moduladores del factor del complemento b
|
CN105793423A
(zh)
|
2013-10-02 |
2016-07-20 |
阿尔尼拉姆医药品有限公司 |
用于抑制lect2基因表达的组合物和方法
|
EP3052521A1
(de)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
|
EP3052107B1
(de)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organische verbindungen zur behandlung von hepatitis-b-infektionen
|
EP3052464B1
(de)
|
2013-10-04 |
2020-04-15 |
Novartis AG |
3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
|
JP6613227B2
(ja)
|
2013-10-04 |
2019-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Alas1遺伝子の発現を阻害する組成物および方法
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CN105899679A
(zh)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
与循环肿瘤细胞簇有关的方法以及癌症的治疗
|
WO2015061246A1
(en)
|
2013-10-21 |
2015-04-30 |
Isis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
US10028902B2
(en)
|
2013-11-08 |
2018-07-24 |
Baylor Research Institute |
Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
WO2015126502A2
(en)
|
2013-12-03 |
2015-08-27 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
CN111729090A
(zh)
|
2013-12-20 |
2020-10-02 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
NZ720286A
(en)
|
2013-12-24 |
2022-12-23 |
Ionis Pharmaceuticals Inc |
Modulation of angiopoietin-like 3 expression
|
EP3102197B1
(de)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
WO2015123264A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015123551A1
(en)
|
2014-02-13 |
2015-08-20 |
Du Luqin |
Microrna composition for the treatment of neuroblastoma
|
EP3119789B1
(de)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
|
RU2019130898A
(ru)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии атаксина 2
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
RU2704619C2
(ru)
|
2014-04-01 |
2019-10-30 |
Биоген Ма Инк. |
Композиции для модулирования экспрессии sod-1
|
EP3943607A1
(de)
|
2014-04-09 |
2022-01-26 |
The Scripps Research Institute |
Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
|
EP4162940A1
(de)
|
2014-04-17 |
2023-04-12 |
Biogen MA Inc. |
Zusammensetzungen und verfahren zur modulation der smn2-aufspaltung in einem patienten
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
EP3811977A1
(de)
|
2014-05-01 |
2021-04-28 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur synthese von reaktiven konjugatclustern
|
EP3137604B1
(de)
|
2014-05-01 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulierung der wachstumshormonrezeptorexpression
|
AU2015252917B2
(en)
|
2014-05-01 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating PKK expression
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
EA201692370A1
(ru)
|
2014-05-22 |
2017-03-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
BR112016028211A2
(pt)
|
2014-06-02 |
2017-10-24 |
Childrens Medical Center |
métodos e composições para imunomodulação
|
CN106661580B
(zh)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
用于治疗庞帕病的反义寡核苷酸
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
MX2017001432A
(es)
|
2014-07-31 |
2017-05-09 |
Uab Res Found |
Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
|
CA2958431A1
(en)
|
2014-08-19 |
2016-02-25 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
CN107106704A
(zh)
|
2014-08-29 |
2017-08-29 |
儿童医疗中心有限公司 |
用于治疗癌症的方法和组合物
|
WO2016033326A2
(en)
|
2014-08-29 |
2016-03-03 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
JP2017529082A
(ja)
|
2014-09-18 |
2017-10-05 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
ハンチントン病ハプロタイプのための対立遺伝子特異的な療法
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
PE20171061A1
(es)
|
2014-11-10 |
2017-07-21 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones farmaceuticas de accion prolongada para hepatitis c
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
CN107206089A
(zh)
|
2014-11-10 |
2017-09-26 |
葛兰素史克知识产权第二有限公司 |
用于丙型肝炎的联合长效组合物和方法
|
CN107250362B
(zh)
|
2014-11-17 |
2021-10-22 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
CN107106493A
(zh)
|
2014-11-21 |
2017-08-29 |
西北大学 |
球形核酸纳米颗粒缀合物的序列特异性细胞摄取
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US11421229B2
(en)
|
2015-02-20 |
2022-08-23 |
Baylor College Of Medicine |
p63 inactivation for the treatment of heart failure
|
WO2016137923A1
(en)
|
2015-02-23 |
2016-09-01 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2016138353A1
(en)
|
2015-02-26 |
2016-09-01 |
Ionis Pharmaceuticals, Inc. |
Allele specific modulators of p23h rhodopsin
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
MX2017012407A
(es)
|
2015-03-27 |
2018-03-07 |
Harvard College |
Celulas t modificadas y métodos para hacer y usar las mismas.
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
RS60230B1
(sr)
|
2015-04-16 |
2020-06-30 |
Ionis Pharmaceuticals Inc |
Kompozicije za moduliranje ekspresije c9orf72
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
EP3919619A1
(de)
|
2015-07-17 |
2021-12-08 |
Alnylam Pharmaceuticals, Inc. |
Mehrfach gerichtete einheitlichen konjugate
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
CN114525280A
(zh)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
CA2998898A1
(en)
|
2015-10-08 |
2017-04-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
JP7441002B2
(ja)
|
2015-10-14 |
2024-02-29 |
バイオ-パス ホールディングス, インコーポレイテッド |
リポソーム製剤のためのp-エトキシ核酸
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
SI3368578T1
(sl)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti HtrA1 in postopki uporabe
|
WO2017075670A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
PE20181180A1
(es)
|
2015-11-06 |
2018-07-20 |
Ionis Pharmaceuticals Inc |
MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3418289A4
(de)
*
|
2016-02-17 |
2019-10-30 |
Tokyo Institute of Technology |
Künstliches nukleosid und künstliches nukleotid und künstliches oligonukleotid
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
US20190177391A1
(en)
|
2016-03-31 |
2019-06-13 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
WO2018015936A2
(en)
|
2016-07-21 |
2018-01-25 |
Maxcyte, Inc. |
Methods and compositions for modifying genomic dna
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG11201901667TA
(en)
|
2016-09-16 |
2019-03-28 |
Bio Path Holdings Inc |
Combination therapy with liposomal antisense oligonucleotides
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
IL301053A
(en)
|
2017-01-23 |
2023-05-01 |
Regeneron Pharma |
HSD17B13 variants and their uses
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
AU2018254437A1
(en)
|
2017-04-18 |
2019-11-28 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis B virus (HBV) infection
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
JP2020517613A
(ja)
|
2017-04-20 |
2020-06-18 |
シンセナ アーゲー |
トリシクロdnaヌクレオシドを含む改変オリゴマー化合物およびその使用
|
CN111051512A
(zh)
|
2017-07-11 |
2020-04-21 |
辛索克斯公司 |
非天然核苷酸的掺入及其方法
|
WO2019014530A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
LACTATE DEHYDROGENASE A (LDHA) RNAI COMPOSITIONS AND METHODS OF USE
|
EP3652186A4
(de)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln
|
WO2019028425A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
WO2019086603A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
AU2018388484A1
(en)
|
2017-12-18 |
2020-07-30 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (HMGB1) iRNA compositions and methods of use thereof
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
EP3752164A1
(de)
|
2018-02-12 |
2020-12-23 |
InteRNA Technologies B.V. |
Antikrebs-mikrorna und lipidformulierungen davon
|
KR20200127207A
(ko)
|
2018-02-26 |
2020-11-10 |
신톡스, 인크. |
Il-15 접합체 및 이의 용도
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
CN116536272A
(zh)
|
2018-04-06 |
2023-08-04 |
儿童医疗中心有限公司 |
用于体细胞重新编程和调整印记的组合物和方法
|
SG11202008660TA
(en)
|
2018-04-11 |
2020-10-29 |
Ionis Pharmaceuticals Inc |
Modulators of ezh2 expression
|
BR112020022546A8
(pt)
|
2018-05-07 |
2022-05-17 |
Alnylam Pharmaceuticals Inc |
Entrega extra-hepática
|
CR20200604A
(es)
|
2018-05-09 |
2021-02-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir de la expresión de atxn3
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
US11332746B1
(en)
|
2018-06-27 |
2022-05-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing LRRK2 expression
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
BR112021001613A2
(pt)
|
2018-08-13 |
2021-05-04 |
Alnylam Pharmaceuticals, Inc. |
agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US20220056220A1
(en)
|
2018-09-14 |
2022-02-24 |
Northwestern University |
Programming protein polymerization with dna
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202028465A
(zh)
|
2018-09-28 |
2020-08-01 |
美商阿尼拉製藥公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
BR112021008967A2
(pt)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de irf5
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
EP4285929A3
(de)
|
2018-12-20 |
2024-03-06 |
Humabs Biomed SA |
Kombinierte hbv-therapie
|
SG11202107669WA
(en)
|
2019-01-16 |
2021-08-30 |
Genzyme Corp |
Serpinc1 irna compositions and methods of use thereof
|
JP2022519532A
(ja)
|
2019-01-31 |
2022-03-24 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Yap1発現のモジュレーター
|
AU2020218203A1
(en)
|
2019-02-06 |
2021-08-26 |
Synthorx, Inc. |
IL-2 conjugates and methods of use thereof
|
AU2020227824A1
(en)
|
2019-02-27 |
2021-08-26 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
SG11202110674XA
(en)
|
2019-03-29 |
2021-10-28 |
Mitsubishi Tanabe Pharma Corp |
Compound, method and pharmaceutical composition for modulating expression of dux4
|
WO2020205463A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
BR112021022806A2
(pt)
|
2019-05-13 |
2022-01-25 |
Vir Biotechnology Inc |
Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit
|
JP2022532652A
(ja)
|
2019-05-17 |
2022-07-15 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
オリゴヌクレオチドの経口送達
|
US11879145B2
(en)
|
2019-06-14 |
2024-01-23 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
CN114340664A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
EP3956450A4
(de)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation von gfap
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CN114555128A
(zh)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
采用il-2缀合物的免疫肿瘤学组合疗法
|
EP4013767A4
(de)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomere verbindungen und ihre verwendungen
|
KR20220051355A
(ko)
|
2019-08-23 |
2022-04-26 |
신톡스, 인크. |
Il-15 콘쥬게이트 및 이의 용도
|
EP4025694A1
(de)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum hemmen der lect2-genexpression
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
JP2022554272A
(ja)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
インターロイキン10コンジュゲートおよびその使用
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
KR20220110749A
(ko)
|
2019-11-06 |
2022-08-09 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
MX2022006433A
(es)
|
2019-12-13 |
2022-06-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
CN115427571A
(zh)
|
2020-02-10 |
2022-12-02 |
阿尔尼拉姆医药品有限公司 |
沉默vegf-a表达的组合物和方法
|
MX2022010052A
(es)
|
2020-02-18 |
2022-09-05 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) contra la apolipoproteina c3 (apoc3) y metodos para su uso.
|
TW202140787A
(zh)
|
2020-02-28 |
2021-11-01 |
美商Ionis製藥公司 |
用於調節smn2之化合物及方法
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
CN116134135A
(zh)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
用于沉默scn9a表达的组合物和方法
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
IRNA compounds complement factor b (cfb) and methods of using them
|
EP4143321A2
(de)
|
2020-05-01 |
2023-03-08 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulierung von atxn1
|
CN115667513A
(zh)
|
2020-05-12 |
2023-01-31 |
田边三菱制药株式会社 |
用于调节Ataxin 3表达的化合物、方法和药物组合物
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4161552A1
(de)
|
2020-06-05 |
2023-04-12 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von neoplasien
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
BR112022024420A2
(pt)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
|
CA3182458A1
(en)
|
2020-06-24 |
2021-12-30 |
Laura ROSEN |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
AU2021296622A1
(en)
|
2020-06-25 |
2023-02-23 |
Synthorx, Inc. |
Immuno oncology combination therapy with IL-2 conjugates and anti-EGFR antibodies
|
JP2023532518A
(ja)
|
2020-06-29 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Plp1を調節するための化合物及び方法
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
BR112023006024A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapias de imuno-oncologia com conjugados de il-2
|
MX2023004029A
(es)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023549500A
(ja)
|
2020-11-13 |
2023-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
凝固第V因子(F5)iRNA組成物およびその使用方法
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
EP4271695A2
(de)
|
2020-12-31 |
2023-11-08 |
Alnylam Pharmaceuticals, Inc. |
Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
|
AU2021411579A1
(en)
|
2020-12-31 |
2023-07-13 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
WO2022182574A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
JP2024512635A
(ja)
|
2021-03-29 |
2024-03-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン(HTT)iRNA剤組成物およびその使用方法
|
AU2022249318A1
(en)
|
2021-03-31 |
2023-10-12 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
KR20240001207A
(ko)
|
2021-04-26 |
2024-01-03 |
알닐람 파마슈티칼스 인코포레이티드 |
막관통 프로테아제, 세린 6(TMPRSS6) iRNA 조성물 및 이의 사용 방법
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
CA3218805A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for intracellular therapeutics
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
CN117500815A
(zh)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
用于降低ifnar1表达的化合物和方法
|
CA3222824A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
WO2023034817A1
(en)
|
2021-09-01 |
2023-03-09 |
Entrada Therapeutics, Inc. |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|